These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 25754914)

  • 1. Complete disappearance of liver metastases in a patient with iodine-refractory differentiated thyroid cancer subjected to sorafenib re-challenge.
    Marotta V; Colao A; Faggiano A
    Endocrine; 2015 Dec; 50(3):824-5. PubMed ID: 25754914
    [No Abstract]   [Full Text] [Related]  

  • 2. Second-line sunitinib as a feasible approach for iodine-refractory differentiated thyroid cancer after the failure of first-line sorafenib.
    Marotta V; Di Somma C; Rubino M; Sciammarella C; Modica R; Camera L; Del Prete M; Marciello F; Ramundo V; Circelli L; Buonomano P; Colao A; Faggiano A
    Endocrine; 2015 Aug; 49(3):854-8. PubMed ID: 25305056
    [No Abstract]   [Full Text] [Related]  

  • 3. Sorafenib in the treatment of thyroid cancer.
    Ferrari SM; Politti U; Spisni R; Materazzi G; Baldini E; Ulisse S; Miccoli P; Antonelli A; Fallahi P
    Expert Rev Anticancer Ther; 2015; 15(8):863-74. PubMed ID: 26152651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.
    Massicotte MH; Brassard M; Claude-Desroches M; Borget I; Bonichon F; Giraudet AL; Do Cao C; Chougnet CN; Leboulleux S; Baudin E; Schlumberger M; de la Fouchardière C
    Eur J Endocrinol; 2014 Apr; 170(4):575-82. PubMed ID: 24424318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorafenib in the treatment of radioiodine-refractory differentiated thyroid cancer: a meta-analysis.
    Shen CT; Qiu ZL; Luo QY
    Endocr Relat Cancer; 2014 Apr; 21(2):253-61. PubMed ID: 24302666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorafenib: 10 years after the first pivotal trial.
    Gadaleta-Caldarola G; Infusino S; Divella R; Ferraro E; Mazzocca A; De Rose F; Filippelli G; Abbate I; Brandi M
    Future Oncol; 2015; 11(13):1863-80. PubMed ID: 26161924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib treatment of radioiodine-refractory advanced thyroid cancer in daily clinical practice: a cohort study from a single center.
    Gallo M; Michelon F; Castiglione A; Felicetti F; Viansone AA; Nervo A; Zichi C; Ciccone G; Piovesan A; Arvat E
    Endocrine; 2015 Aug; 49(3):726-34. PubMed ID: 25414068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of sorafenib in hepatocellular carcinoma.
    Gholam P
    Clin Adv Hematol Oncol; 2015 Apr; 13(4):232-4. PubMed ID: 26352581
    [No Abstract]   [Full Text] [Related]  

  • 9. Targeted treatments of radio-iodine refractory differentiated thyroid cancer.
    de la Fouchardière C
    Ann Endocrinol (Paris); 2015 Feb; 76(1 Suppl 1):1S34-9. PubMed ID: 26826481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The discovery and development of sorafenib for the treatment of thyroid cancer.
    White PT; Cohen MS
    Expert Opin Drug Discov; 2015 Apr; 10(4):427-39. PubMed ID: 25662396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid carcinoma: a systematic review and indirect comparison with sorafenib.
    Kawalec P; Malinowska-Lipień I; Brzostek T; Kózka M
    Expert Rev Anticancer Ther; 2016 Dec; 16(12):1303-1309. PubMed ID: 27734713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Which patient with thyroid cancer deserves systemic therapy and when?
    Pacini F
    Best Pract Res Clin Endocrinol Metab; 2017 Jun; 31(3):291-294. PubMed ID: 28911725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. pAKT Expression and Response to Sorafenib in Differentiated Thyroid Cancer.
    Yarchoan M; Ma C; Troxel AB; Stopenski SJ; Tang W; Cohen AB; Pappas-Paxinos M; Johnson BA; Chen EY; Feldman MD; Brose MS
    Horm Cancer; 2016 Jun; 7(3):188-95. PubMed ID: 26994002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic management of metastatic medullary thyroid carcinoma: role of new tyrosine kinase inhibitors.
    García-Martín A; López-Ibarra Lozano PJ; Triviño-Ibáñez EM; Escobar-Jiménez F
    Endocrinol Nutr; 2013 Mar; 60(3):152-3. PubMed ID: 22565118
    [No Abstract]   [Full Text] [Related]  

  • 15. Inhibition of the AKT/mTOR Pathway Augments the Anticancer Effects of Sorafenib in Thyroid Cancer.
    Yi H; Ye X; Long B; Ye T; Zhang L; Yan F; Yang Y; Li L
    Cancer Biother Radiopharm; 2017 Jun; 32(5):176-183. PubMed ID: 28622037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. More effective agents still needed for progressive radioiodine-refractory differentiated thyroid cancer.
    Shen CT; Qiu ZL; Luo QY
    Endocr Relat Cancer; 2014 Apr; 21(2):L3-4. PubMed ID: 24639563
    [No Abstract]   [Full Text] [Related]  

  • 17. Timing of multikinase inhibitor initiation in differentiated thyroid cancer.
    Brose MS; Smit J; Lin CC; Pitoia F; Fellous M; DeSanctis Y; Schlumberger M; Tori M; Sugitani I
    Endocr Relat Cancer; 2017 May; 24(5):237-242. PubMed ID: 28270435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib (Nexavar) for thyroid cancer.
    Med Lett Drugs Ther; 2014 May; 56(1443):43-4. PubMed ID: 24869715
    [No Abstract]   [Full Text] [Related]  

  • 19. Sorafenib and thyroid cancer.
    Fallahi P; Ferrari SM; Santini F; Corrado A; Materazzi G; Ulisse S; Miccoli P; Antonelli A
    BioDrugs; 2013 Dec; 27(6):615-28. PubMed ID: 23818056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Off-label use of Sorafenib in patients with advanced thyroid carcinoma: Retrospective analysis of five cases.
    Bugalho MJ
    J Cancer Res Ther; 2016; 12(2):1084-7. PubMed ID: 27461704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.